Filing Analysis
Bankruptcy
Filed Mar 31, 2026
CRITICAL
IO Biotech, Inc. has filed for voluntary Chapter 7 bankruptcy protection, ceased all operations, and terminated all employees and officers. The company expects that common stockholders will receive no distribution and has announced it will no longer file periodic reports with the SEC.
Red Flags
- Chapter 7 bankruptcy filing (liquidation rather than reorganization).
- Cessation of all business operations.
- Default on €22.5 million in debt to the European Investment Bank.
- Total resignation of the Board of Directors and termination of all staff.
- Explicit warning that common stock is likely worthless.
- Cessation of SEC reporting obligations.
Key Facts
- Filed a voluntary petition for relief under Chapter 7 of the Bankruptcy Code on March 31, 2026, in the District of Delaware.
- The filing triggers an event of default on a finance contract with the European Investment Bank (EIB) for €22.5 million.
- All six members of the Board of Directors resigned effective March 31, 2026.
- All employees and officers, including CEO Mai-Britt Zocca and CFO Amy Sullivan, were terminated without cause.
- The company will not complete its 2025 audit or file its Form 10-K for the fiscal year ended December 31, 2025.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.